Osaka, Japan, December 2, 2025. Luxna Biotech Co., Ltd. (President CEO: Hideaki Sato; Headquarters: Suita-shi, Osaka, Japan, hereinafter “Luxna”) and..
November 10, 2025
From Discovery to Commercial Supply: Accelerating the Development of Therapeutic Oligonucleotide Drugs
Frankfurt a.M. / Munich, November 10th, 2025. BioSpring, a world-leading CDMO for therapeutic oligonucleotide manufacturing and analysis, and..
October 9, 2025
BioSpring Enters Strategic Partnership with Luxna Biotech to Offer Manufacture of Oligonucleotides with Luxna’s advanced XNA Amidites
Frankfurt am Main, Germany. BioSpring, a leading supplier of high-quality therapeutic oligonucleotides, today announced a new collaboration with..
August 28, 2025
The World Visits BioSpring: Consular Corps Tours Frankfurt High-Tech Company
Frankfurt am Main, Germany. Around 70 career and honorary consuls from all over the world visited the Frankfurt-based high-tech company BioSpring as..
